

1615

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

PRICE

Serial No.: 09/125,114

Filed: August 18, 1998

For: DOSAGE FORM OF IBUPROFEN



Group Art Unit: 1615

Examiner: Berman, A.

#11
#KID
4-18-00

**SUPPLEMENTAL RESPONSE TO OFFICE ACTION AND
NOTIFICATION OF CHANGE OF NAME AND ADDRESS**

Assistant Commissioner for Patents
Washington, D.C. 20231

March 13, 2000

RECEIVED
MAR 15 2000
TC 1600 MAIL ROOM

Sir:

This is a Supplemental Response to the Office Action mailed October 13, 1999.

Kindly change the correspondence name and address for the above-identified application to the following:

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 Connecticut Avenue, NW, Suite 600
Washington, DC 20036-5339
Telephone: (202) 857-6000
Telefax: (202) 638-4810

REMARKS

Applicant's arguments presented in the Response filed on March 10, 2000 against the obviousness rejection of claims 1 and 11 also apply to the obviousness rejection of other claims, e.g. claims 16-18, 20-22 and 24-26. Additionally, applicant submits that Geisslinger in view of Gregory and further in view of Elger would not have rendered obvious claims 16-18, 20-22 and 24-26. Withdrawal of the rejection of claims 16-18, 20-22 and 24-26 is requested.

Should any fees be due with respect to this paper, please charge Counsel's Deposit

Account No. 01-2300.

Respectfully submitted,
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC

King L. Wong

King L. Wong
Attorney for Applicant
Reg. No. 37,500

Atty. Docket No. 108129-08004
1050 Connecticut Avenue, NW
Suite 600
Washington, DC 20036-5339
Tel: (202) 828-3455

RECEIVED
MAR 15 2000
TC 1600 MAIL ROOM